Page 14 - Serum Institute Of India

Expert panel recommends approval to Russia's Sputnik V Covid-19 vaccine

Now, the Drugs Controller General of India DCGI will consider this recommendation and decide whether to grant Sputnik V approval for restricted emergency use in India

Covid-19 vaccine: Real-world data to decide commercial marketing approval

Two such vaccines are Covishield, made by the Serum Institute of India (SII), and Covaxin by Bharat Biotech

Failure on vaccines

Refusal to support private sector has led to a roll-out flop

Will stop Serum's vehicles if doses not given to Maharashtra: Raju Shetti

He claimed people in Maharashtra are angry over not getting the vaccine, and many vaccination centres are closed due to the shortage of doses

Covid-19 vaccination sites drop to half in India amid shortage of doses

Number of locations down from 120,000 to 60,000 from April 3 to 7

Serum Institute is legally bound to supply Covid-19 vaccines: COVAX

SII partner AstraZeneca has already issued it a legal notice over delays to other shipments, even as many Indian states have complained of a shortage facing priority recipients.

Is it safe? Global concern over the use of AstraZeneca vaccine explained

In India, Serum Institute of India is manufacturing AstraZeneca's vaccine under the brand Covishield

'Equitable distribution': Covax says Serum bound to supply virus vaccines

India could resume vaccine exports by June, the firm's chief executive, Adar Poonawalla, told media this week

WHO rejects SII's proposal for extension of Covishield's shelf life: Report

The WHO has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca Covid-19 vaccine, Covishield, from six to nine months, citing insufficient data

African Union drops plans to buy Covid vaccines from Serum, pivots to J&J

The statement comes the day after European and British medicine regulators said they had found possible links between AstraZeneca's vaccine and reports of very rare cases of brain blood clots

Link between AstraZeneca vaccine and blood clots unclear: EMA official

There is a causal link between the coronavirus vaccine developed by AstraZeneca and very rare cases of blood clots, said a senior European Medicines Agency (EMA) expert

AstraZeneca has sent us legal notice for vaccine supply delay: Poonawalla

For the next one or two months, we will be prioritising supplies only to India based on the request of the government and also depending on the needs of our people, said Poonawalla

India could resume Covid-19 vaccine exports by June: Adar Poonawalla

The world's largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said Tuesday

India blessed to have Serum Institute: World Bank President David Malpass

World Bank President David Malpass has said that he is encouraged by the country's domestic vaccination programme

SII to start supplying 1st India-made pneumococcal conjugate jab to govt

The Serum Institute of India (SII) will start supplying the first indigenously developed pneumococcal conjugate vaccine to the Centre from Wednesday, sources said on Tuesday

Serum Institute may apply to sell Covid-19 vaccine Covishield commercially

No Covid vaccine in the world has marketing authorisation allowing sales in private market

Sri Lanka temporarily halts Covid jabs on delay in procurement from Serum

Sri Lanka has temporarily halted its Covid-19 vaccination programme as there was a delay in securing more AstraZeneca vaccines from the Serum Institute of India, a top health minister has said

Supply chain threats

Vaccine nationalism shows how the pandemic has stressed trade

At $2.06 per dose, India pays the least for AstraZeneca Covid-19 vaccine

The price paid by different governments for a vaccine dose - including for the same vaccine - varies across countries, Unicef data shows

SII, Bharat Bio seek central fund injection to ramp up vaccine production

SII, Bharat Biotech want to increase production to meet domestic, foreign demand